| |
|
Pathologies [%] |
| Author |
n |
AD lesions |
AD alone |
AD+ CVL |
AD+ LBD |
VaD |
| Nolan et al. '98 [285] |
87 |
87 |
50 |
34 |
– |
– |
| Lim et al. '99 [286] |
? |
AD cases |
36 |
45 |
22 |
– |
| NUN study - Riley et al. '02 [287] |
|
AD cases |
57 |
73/93 |
– |
– |
| HAAS study - Petrovitch '05 [281] |
333 |
< 60 |
36 |
24 |
– |
24 |
| MRC-CFAS (UK) (Fernando-Ince '04) [268] |
209 (48% dem.) |
70 |
21 |
– |
– |
78 |
| Andin et al. '05 [288] |
175 (clin. VaD) |
– |
72 |
– |
28 |
|
| Schneider et al. '07 [237] |
141 |
82.7 |
30 |
38 |
12 |
12 |
| Jellinger '08 (retrospective) [172] |
1700 (dem.) |
82.9 |
48.0 |
19.0 |
9.1 |
10.7 |
| Jellinger (prospective, unpubl.) |
180 |
82.7 |
48.8 |
23.9 |
10.0 |
7.8 |
| Kovacs et al. '13 [289]
(other pathologies 23.2%) |
233 |
100 |
12 |
48.9 |
24 |
? |
